Year-over-year earnings per share growth for the last twelve months: Harpoon Therapeutics (HARP)

harpoontx.com (HARP) - corporate logo

The development of Harpoon Therapeutics (HARP) depends on the results of clinical trials for anti-tumor drugs amid a stable liquidity reserve. A scientific approach prevails within the company, supporting researcher autonomy through RSU packages. The use of the TriTAC platform for T-cell activation determines the growth rates of quarterly net income per share, where the 86.40 mark reflects fresh data on the business's fundamental efficiency.

Harpoon Therapeutics Inc (HARP) Year-over-year net earnings per share growth for the last 12 months: for the period 07/04/2022 - 03/16/2024

Comprehensive metric breakdowns and analytics for harpoontx.com (HARP)

Comprehensive company analysis:Harpoon Therapeutics Inc, HARP
Manufactured product of Harpoon Therapeutics

Quarterly EPS growth measures the dynamics of net income per share, allowing for an assessment of the pace of earnings recovery and capital management efficiency during a crisis exit. By analyzing the history of quarterly EPS changes, an investor can benchmark the financial progress of Harpoon Therapeutics (HARP) against the success of the TriTAC platform and its ability to attract partners for combating tumors.

Competitors of Harpoon Therapeutics

IBRX: Quarterly EPS earnings growth|IMCR - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months januxrx.com|Year-over-year net earnings per share growth for the last 12 months arcusbio.com (RCUS)|Year-over-year earnings per share growth for the last twelve months Zymeworks Inc (ZYME)|Year-over-year net earnings per share growth for the last 12 months Tango Pharma TNGX|Iovance Biotherapeutics Inc - Year-over-year net earnings per share growth for the last 12 months|Quarterly EPS earnings growth Immatics Biotechnologies IMTX|XNCR - Year-over-year earnings per share growth for the last twelve months|CMPX (compasstherapeutics.com) - Year-over-year earnings per share growth for the last 12 months|Replimune Inc. (REPL) - Year-over-year earnings per share growth for the last twelve months|Earnings per share growth in annualized terms for the last twelve months Lyell Immunopharma Inc (LYEL)|Year-over-year net earnings per share growth for the last 12 months IPHA|PYXS - Net earnings per share growth for the trailing year|Year-over-year net earnings per share growth for the last 12 months CGEN (Compugen Ltd.)|Year-over-year earnings per share growth rate for the last twelve months IOBT|Quarterly EPS earnings growth STRO (Sutro Biopharma)|Year-over-year earnings per one share growth for the last 12 months INKT|Werewolf - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Immix Biopharma|ALX Oncology (ALXO) - Year-over-year earnings per share growth for the last twelve months|cuebiopharma.com (CUE) - Quarterly EPS earnings growth|PDSB (PDS Biotechnology Corp) - Quarterly EPS earnings growth|Quarterly EPS earnings growth sonnetbio.com|Year-over-year earnings per share growth for the last twelve months MAIA Biotechnology, Inc. (MAIA)|LIMN: Year-over-year net earnings per share trend for the last twelve months|LAVA Therapeutics - Year-over-year net earnings per share growth for the last 12 months|nextcure.com (NXTC) - Earnings per share growth in annualized terms for the last twelve months|LPTX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Intensity Therapeutics, Inc. INTS|SNSE: Quarterly EPS earnings growth|Synthetic Biologics - Year-over-year earnings per one share growth for the last 12 months|GRTS (Gritstone bio) - Quarterly EPS earnings growth|KA (Kineta, Inc.) - Year-over-year earnings per share growth rate for the last twelve months|Quarterly EPS earnings growth NEXI|Turnstone Biologics Corp - Year-over-year earnings per share growth for the last 12 months|Quarterly EPS earnings growth VCNX (Vaccinex Inc)